419 related items for PubMed ID: 29750317
1. Mycophenolate mofetil for sustained remission in nephrotic syndrome.
Querfeld U, Weber LT.
Pediatr Nephrol; 2018 Dec; 33(12):2253-2265. PubMed ID: 29750317
[Abstract] [Full Text] [Related]
2. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T, Sako M, Nakanishi K, Ishikura K, Ito S, Nakamura H, Oba MS, Nozu K, Iijima K.
BMC Nephrol; 2018 Nov 01; 19(1):302. PubMed ID: 30382824
[Abstract] [Full Text] [Related]
3. Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome.
Sinha A, Gupta A, Kalaivani M, Hari P, Dinda AK, Bagga A.
Kidney Int; 2017 Jul 01; 92(1):248-257. PubMed ID: 28318625
[Abstract] [Full Text] [Related]
4. Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome.
Wang J, Mao J, Chen J, Fu H, Shen H, Zhu X, Liu A, Shu Q, Du L.
Nephrology (Carlton); 2016 Jan 01; 21(1):21-7. PubMed ID: 26697959
[Abstract] [Full Text] [Related]
5. Three year outcome of childhood idiopathic nephrotic syndrome under a unified immunosuppressive protocol.
Hibino S, Uemura O, Nagai T, Yamakawa S, Iwata N, Ito H, Nakano M, Tanaka K.
Pediatr Int; 2015 Jan 01; 57(1):85-91. PubMed ID: 25225083
[Abstract] [Full Text] [Related]
6. Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome.
Barletta GM, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB.
Pediatr Nephrol; 2003 Aug 01; 18(8):833-7. PubMed ID: 12774223
[Abstract] [Full Text] [Related]
7. Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children.
Basu B, Babu BG, Mahapatra TK.
Clin Exp Nephrol; 2017 Feb 01; 21(1):143-151. PubMed ID: 27108294
[Abstract] [Full Text] [Related]
8. Long-term outcome of Japanese children with complicated minimal change nephrotic syndrome treated with mycophenolate mofetil after cyclosporine.
Fujinaga S, Hirano D, Nishino T, Umeda C, Watanabe Y, Nakagawa M.
Pediatr Nephrol; 2019 Nov 01; 34(11):2417-2421. PubMed ID: 31435725
[Abstract] [Full Text] [Related]
9. Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome.
Gellermann J, Ehrich JH, Querfeld U.
Nephrol Dial Transplant; 2012 May 01; 27(5):1970-8. PubMed ID: 21976740
[Abstract] [Full Text] [Related]
10. Mycophenolate mofetil therapy for children with intractable nephrotic syndrome.
Okada M, Sugimoto K, Yagi K, Yanagida H, Tabata N, Takemura T.
Pediatr Int; 2007 Dec 01; 49(6):933-7. PubMed ID: 18045300
[Abstract] [Full Text] [Related]
11. Triple immunosuppressive therapy in steroid-resistant nephrotic syndrome children with tacrolimus resistance or tacrolimus sensitivity but frequently relapsing.
Wu B, Mao J, Shen H, Fu H, Wang J, Liu A, Gu W, Shu Q, Du L.
Nephrology (Carlton); 2015 Jan 01; 20(1):18-24. PubMed ID: 25312783
[Abstract] [Full Text] [Related]
12. Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome.
Iijima K, Sako M, Oba M, Tanaka S, Hamada R, Sakai T, Ohwada Y, Ninchoji T, Yamamura T, Machida H, Shima Y, Tanaka R, Kaito H, Araki Y, Morohashi T, Kumagai N, Gotoh Y, Ikezumi Y, Kubota T, Kamei K, Fujita N, Ohtsuka Y, Okamoto T, Yamada T, Tanaka E, Shimizu M, Horinochi T, Konishi A, Omori T, Nakanishi K, Ishikura K, Ito S, Nakamura H, Nozu K, Japanese Study Group of Kidney Disease in Children.
J Am Soc Nephrol; 2022 Feb 01; 33(2):401-419. PubMed ID: 34880074
[Abstract] [Full Text] [Related]
13. Idiopathic nephrotic syndrome in Syrian children: clinicopathological spectrum, treatment, and outcomes.
Wannous H.
Pediatr Nephrol; 2024 Aug 01; 39(8):2413-2422. PubMed ID: 38587559
[Abstract] [Full Text] [Related]
14. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Hodson EM, Wong SC, Willis NS, Craig JC.
Cochrane Database Syst Rev; 2016 Oct 11; 10(10):CD003594. PubMed ID: 27726125
[Abstract] [Full Text] [Related]
15. Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions.
Moudgil A, Bagga A, Jordan SC.
Pediatr Nephrol; 2005 Oct 11; 20(10):1376-81. PubMed ID: 15977023
[Abstract] [Full Text] [Related]
16. Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options.
Kemper MJ, Valentin L, van Husen M.
Pediatr Nephrol; 2018 Oct 11; 33(10):1641-1649. PubMed ID: 28879428
[Abstract] [Full Text] [Related]
17. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome.
Bagga A, Hari P, Moudgil A, Jordan SC.
Am J Kidney Dis; 2003 Dec 11; 42(6):1114-20. PubMed ID: 14655181
[Abstract] [Full Text] [Related]
18. A comparison of a standard-dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study.
Li X, Tian J, Wu J, He Q, Li H, Han F, Li Q, Chen Y, Ni Q, Chen J.
Clin Ther; 2009 Apr 11; 31(4):741-50. PubMed ID: 19446147
[Abstract] [Full Text] [Related]
19. Pharmacokinetics of mycophenolic acid in children with clinically stable idiopathic nephrotic syndrome receiving cyclosporine.
Hibino S, Nagai T, Yamakawa S, Ito H, Tanaka K, Uemura O.
Clin Exp Nephrol; 2017 Feb 11; 21(1):152-158. PubMed ID: 27105859
[Abstract] [Full Text] [Related]
20. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome.
Mendizábal S, Zamora I, Berbel O, Sanahuja MJ, Fuentes J, Simon J.
Pediatr Nephrol; 2005 Jul 11; 20(7):914-9. PubMed ID: 15891923
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
